Literature DB >> 24174400

High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Rajoshi Chaudhuri1, Yuan Cheng, C Russell Middaugh, David B Volkin.   

Abstract

Stabilization and formulation of therapeutic proteins against physical instability, both structural alterations and aggregation, is particularly challenging not only due to each protein's unique physicochemical characteristics but also their susceptibility to the surrounding milieu (pH, ionic strength, excipients, etc.) as well as various environmental stresses (temperature, agitation, lyophilization, etc.). The use of high-throughput techniques can significantly aid in the evaluation of stabilizing solution conditions by permitting a more rapid evaluation of a large matrix of possible combinations. In this mini-review, we discuss both key physical degradation pathways observed for protein-based drugs and the utility of various high-throughput biophysical techniques to aid in protein formulation development to minimize their occurrence. We then focus on four illustrative case studies with therapeutic protein candidates of varying sizes, shapes and physicochemical properties to explore different analytical challenges in monitoring protein physical instability. These include an IgG2 monoclonal antibody, an albumin-fusion protein, a recombinant pentameric plasma glycoprotein, and an antibody fragment (Fab). Future challenges and opportunities to improve and apply high-throughput approaches to protein formulation development are also discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24174400      PMCID: PMC3889527          DOI: 10.1208/s12248-013-9539-6

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  96 in total

1.  Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.

Authors:  Tomoyoshi Ishikawa; Takahiko Ito; Ryosuke Endo; Keiko Nakagawa; Eiji Sawa; Kaori Wakamatsu
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

2.  Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.

Authors:  Todd J Gibson; Katie Mccarty; Iain J Mcfadyen; Ethan Cash; Paul Dalmonte; Kenneth D Hinds; Adam A Dinerman; Juan C Alvarez; David B Volkin
Journal:  J Pharm Sci       Date:  2010-10-25       Impact factor: 3.534

3.  Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.

Authors:  Michael D Bond; Mark E Panek; Zheru Zhang; Dana Wang; Promod Mehndiratta; Hui Zhao; Keith Gunton; Alex Ni; Michael L Nedved; Sudhir Burman; David B Volkin
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

4.  Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence.

Authors:  Feng He; Duke H Phan; Sabine Hogan; Robert Bailey; Gerald W Becker; Linda O Narhi; Vladimir I Razinkov
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

5.  2010 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 6.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 7.  Protein aggregation--pathways and influencing factors.

Authors:  Wei Wang; Sandeep Nema; Dirk Teagarden
Journal:  Int J Pharm       Date:  2010-02-24       Impact factor: 5.875

8.  Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.

Authors:  Klaus Wuchner; Jochen Büchler; Rene Spycher; Paul Dalmonte; David B Volkin
Journal:  J Pharm Sci       Date:  2010-08       Impact factor: 3.534

9.  PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis.

Authors:  Jeremy S Duffield; Mark L Lupher
Journal:  Drug News Perspect       Date:  2010-06

10.  Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies.

Authors:  Erinc Sahin; Adeola O Grillo; Melissa D Perkins; Christopher J Roberts
Journal:  J Pharm Sci       Date:  2010-12       Impact factor: 3.534

View more
  27 in total

1.  Bilateral Effects of Excipients on Protein Stability: Preferential Interaction Type of Excipient and Surface Aromatic Hydrophobicity of Protein.

Authors:  Lili Wen; Xianxian Zheng; Xinyue Wang; Hairong Lan; Zongning Yin
Journal:  Pharm Res       Date:  2017-04-11       Impact factor: 4.200

2.  Biosimilars: Imitation Games.

Authors:  Hussain Dahodwala; Susan T Sharfstein
Journal:  ACS Med Chem Lett       Date:  2017-06-09       Impact factor: 4.345

3.  Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometry.

Authors:  Subhashchandra Naik; Ozan S Kumru; Melissa Cullom; Srivalli N Telikepalli; Elizabeth Lindboe; Taylor L Roop; Sangeeta B Joshi; Divya Amin; Phillip Gao; C Russell Middaugh; David B Volkin; Mark T Fisher
Journal:  Protein Sci       Date:  2014-07-28       Impact factor: 6.725

4.  Commentary: current perspectives on the aggregation of protein drugs.

Authors:  Elizabeth M Topp
Journal:  AAPS J       Date:  2014-02-22       Impact factor: 4.009

Review 5.  Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Niccolò Candelise; Salvador Ventura; Franc Llorens; Inga Zerr
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

6.  Experimental Model System to Study pH Shift-Induced Aggregation of Monoclonal Antibodies Under Controlled Conditions.

Authors:  Olubukayo-Opeyemi Oyetayo; Hans Kiefer
Journal:  Pharm Res       Date:  2016-02-29       Impact factor: 4.200

7.  Analysis of IgG kinetic stability by differential scanning calorimetry, probe fluorescence and light scattering.

Authors:  Michal Nemergut; Gabriel Žoldák; Jonas V Schaefer; Florian Kast; Pavol Miškovský; Andreas Plückthun; Erik Sedlák
Journal:  Protein Sci       Date:  2017-09-06       Impact factor: 6.725

8.  Biochemical Characterization of the Cytochrome P450 CYP107CB2 from Bacillus lehensis G1.

Authors:  Swi See Ang; Abu Bakar Salleh; Leow Thean Chor; Yahaya M Normi; Bimo Ario Tejo; Mohd Basyaruddin Abdul Rahman; Mariam-Aisha Fatima
Journal:  Protein J       Date:  2018-04       Impact factor: 2.371

9.  RETRACTED: Peptide-induced formation of protein aggregates and amyloid fibrils in human and guinea pig αA-crystallins under physiological conditions of temperature and pH.

Authors:  Anbarasu Kumarasamy; Sivakumar Jeyarajan; Jonathan Cheon; Anthony Premceski; Eric Seidel; Victoria A Kimler; Frank J Giblin
Journal:  Exp Eye Res       Date:  2018-11-15       Impact factor: 3.467

10.  Role of benzyl alcohol in the unfolding and aggregation of interferon α-2a.

Authors:  Regina L Bis; Surinder M Singh; Javier Cabello-Villegas; Krishna M G Mallela
Journal:  J Pharm Sci       Date:  2014-08-06       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.